Twicor (Rosuvastatin/Ezetimibe) medication

Twicor is a prescription medication used to manage cholesterol levels, combining two active ingredients: rosuvastatin and ezetimibe. It is typically marketed in European regions like Spain to treat primary hypercholesterolemia.

The brand was originally developed under Mylan, an American-founded pharmaceutical company that built a significant presence in the generic and specialty drug market.

Following a strategic merger in late 2020, Mylan combined with Pfizer's Upjohn division to form Viatris. Consequently, Viatris is now the ultimate owner of the brand. Manufacturing of such pharmaceutical products often occurs across a global network of specialized facilities in countries like Hungary, Ireland, or India to ensure international supply chain stability.